[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.173.45. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
October 2015

Reduced Risk of Squamous Cell Carcinoma With Adequate Treatment of Vulvar Lichen Sclerosus

Author Affiliations
  • 1Department of Dermatology, Oxford University Hospitals Trust, Oxford, England
  • 2Department of Dermatology, P. D. Hinduja National Hospital and Medical Research Center, Mumbai, India
  • 3Department of Dermatology, Sir HN Reliance Foundation Hospital, Mumbai, India
  • 4Department of Obstetrics and Gynecology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire
  • 5Department of Surgery (Dermatology), Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire
JAMA Dermatol. 2015;151(10):1059-1060. doi:10.1001/jamadermatol.2015.0644

In this issue, Lee and colleagues1 present the results of the largest prospective clinical cohort study to date concerning 507 women with vulvar lichen sclerosus (VLS). The authors present evidence that poor compliance with topical corticosteroid (TCS) treatment predisposes patients to the development of vulvar cancer and scarring. They propose that initial treatment regimens should be selected using a variety of corticosteroid potencies based on the severity of signs at presentation. They also propose that maintenance treatment for VLS should be the norm, increasing or decreasing the potency of treatment as necessary. The authors recommend life-long specialist follow-up.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    EXPAND ALL
    Response to Management of Adult Vulvar Lichen Sclerosus: Adult Male Genital Perspective
    Doiron PR, Kravvas G, Bunker CB | Chelsea & Westminster Hospital
    Our interest was engaged by the findings of Lee et al1 and the accompanying editorial by Cooper et al2, regarding the management of adult vulvar lichen sclerosus and the observed abolition of the risk of skin cancer.

    Our group works with adult male genital lichen sclerosus (MGLSc) during weekly clinics across two clinical sites in central London. In terms of preventing disease progression, mitigating impact on both sexual and urinary function, and eliminating the risk of intraepithelial neoplasia and invasive carcinoma, our goals are well aligned with those presented by Lee and colleagues.

    Our proactive management strategy, outlined below, differs from
    that presented by Lee and colleagues given the obvious anatomical and attendant structural differences in our respective patient populations. MGLSc is almost exclusively a disease of the uncircumcised male3, thought to result from chronic, intermittent exposure of a susceptible epithelium to urine.4 Typically, our patients are managed initially with a one-month course of ultrapotent topical corticosteroid, barrier emollients and soap substitutes.5 Approximately 50-60% of men respond to this treatment.3,5 If disease is refractory, circumcision is recommended and that is curative in the majority of cases.3,5

    Lee and colleagues have reassuringly demonstrated that in patients who underwent vigilant management of their genital lichen sclerosus, no cases of intraepithelial neoplasia or invasive squamous cell carcinoma (SCC) were seen.1 The findings align with our results from a case series of 329 MGLSc patients, none of whom developed SCC.3 This is in sharp contrast to the rates of 2-12.5%3 published in the literature. This supports the argument that vigilant management of lichen sclerosus mitigates and perhaps even eliminates the risk of SCC, which has been the case in our experience. Anecdotally, none of the approximately 400 MGLSc patients who have been seen in our clinics over the last four years have developed penile intraepithelial neoplasia or invasive SCC. A retrospective project characterizing this cohort of patients is currently underway.

    We congratulate the authors on their important work which arms practitioners with valuable, practical information to assist in clinical decision-making and patient advice.

    Acknowledgements
    Dr. Tang Ngee Shim (Chelsea and Westminster Hospital) for his contributions to the retrospective project currently underway.

    References
    1. Lee A, Bradford J, Fischer G. Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatol. 2015;151(10):1061-67.
    2. Cooper SM, Madnani N, Margesson L. Reduced risk of squamous cell carcinoma with adequate treatment of vulvar lichen sclerosus. JAMA Dermatol. 2015;151(10):1059-60.
    3. Edmonds EV, Hunt S, Hawkins D, Dinneen M, Francis N, Bunker CB. Clinical parameters in male genital lichen sclerosus: a case series of 329 patients. JEADV. 2012;26:730-37.
    4. Bunker CB. Occlusion, urine and genital lichen sclerosus. Indian J Dermatol Venereol Leprol. 2012;78:367-8.
    5. Bunker CB, Shim TN. Male genital lichen sclerosus. Indian J Dermatol. 2015;60(2):111-17.
    CONFLICT OF INTEREST: None Reported
    READ MORE
    ×